Background: Regional lung transplantation centers should be equipped with an interhospital transport program that can provide life-support for lung transplant candidates who develop acute respiratory failure outside the hospital. The purpose of this study was to assess the value of extracorporeal membrane oxygenation (ECMO) as a means of support during transport and as a bridge to lung transplantation for transplant candidates who develop respiratory failure outside the transplantation center. Methods: We retrospectively analyzed data from 7 patients who developed acute lung failure during treatment of end-stage lung diseases at other hospitals and for whom inter-hospital transport to the lung transplantation center at our hospital was requested between December 2011 and June 2013. Results: All 7 patients were treated with ECMO via a Terumo Emergency Bypass System ® (EBS ® ) during transport, and all were transported without incident. There were no adverse events related to ECMO. All patients maintained stable vital signs during transport. Four patients received lung transplant within 10.5 ± 2.3 days (range: 7 to 12 days) after transport, 1 patient was weaned from ECMO without transplant, and 2 patients died with multi-organ failure while awaiting donor lungs. Conclusion: ECMO was useful for transfer of lung transplant candidates who developed acute respiratory failure at other institutions and as a bridge to lung transplantation. An inter-hospital transport program involving ECMO may increase the likelihood of successful transport to regional transplantation centers for lung transplantation candidates who show respiratory failure.
Background
Extracorporeal membrane oxygenation (ECMO) is becoming more widely available as a treatment option for respiratory failure. ECMO can be used as an alternative treatment option for patients with respiratory disease and failure who cannot be treated by more conventional means. 1) In particular, ECMO can provide crucial support as a bridge to lung transplantation for patients with chronic lung failure. It can reduce mortality among patients whose respiratory conditions worsen while they are awaiting donor lungs. 2, 3) However, even as ECMO has become more widely available, there will still be lung transplant candidates who reach end-stage lung failure while in hospitals that are not equipped with ECMO. In order to provide these patients with ECMO as a bridge to lung transplant, they must be transported to the transplant center. As the clinical condition of most end-stage lung disease patients with acute respiratory failure is unstable, it is not possible to transport them by regular means. An inter-hospital transport system equipped with ECMO can save the lives of these patients.
As a regional lung transplantation center, we have established such a system. The purpose of this report is to describe the results obtained using ECMO during transport of lung transplant candidates who developed acute respiratory failure outside our center and analyze the effectiveness of ECMO as a bridge to lung transplantation.
Methods
This is a retrospective report including data from 7 patients who experienced acute lung failure during treatment of end-stage lung diseases at other hospitals and were transported with ECMO via our inter-hospital transport system to our lung transplantation center between December 2011 and June 2013.
Patient selection, evaluation, and preparation
All transport requests are evaluated by the members of the ECMO transportation team on duty at the time they are received. Team members assess the status of the patient based on information from the requesting hospital and decide whether the patient has suitable indication for interhospital transport with ECMO. If so, the ECMO transport team is dispatched ( Table 1) . The ECMO transport equipment includes the Terumo emergency bypass system (EBS ® ; Terumo Corp., Tokyo, Japan) and circuit, cannulas of various sizes, a bag-valve mask (BVM, "Ambubag"), an O 2 line and O 2 tank, an IntelliVue MMS X2 ® (Philips, Amsterdam, The Netherlands) portable vital sign monitoring system, and an infusion pump and I-stat ® (Santair S.A., Athens, Greece) portable blood gas analyzer. When the ECMO transport team arrives at the requesting hospital, the patient's status is reevaluated before transport is attempted. If the patient's cardiac function is normal, a veno-veno (V-V) ECMO bypass is considered, and in those with cardiac compromise, venoarterial (V-A) ECMO is considered and echocardiography is performed to assess the underlying heart condition.
ECMO procedure
Patients are mildly sedated with midazolam (0.07-0.08 mg/kg) and low-dose heparin (3000 IU) is administered prior to cannulation for the ECMO bypass. In cases involving V-V ECMO, the right femoral vein is used for venous drainage and the internal jugular vein is used for venous return; for V-A ECMO, the right femoral vein and the left femoral artery, respectively, are used. The sites are sterilized and the vessels are cannulated using the Seldinger technique under ultrasound guidance, usually with either a FEM-FLEX2 femoral cannula from Edwards Lifesciences or a Medtronic DLP femoral cannula. The cannulas are firmly fixed to the patient's body to prevent decannulation during transport. After cannulation, the ECMO circuit is connected and ECMO via the Terumo EBS ® is initiated. If the patient becomes hypotensive because of the sudden reduction of preload that occurs immediately after starting ECMO, 1000 mL of crystalloid is administered through the ECMO circuit. Once the patient is stabilized on ECMO, the ventilator setting is gradually lowered over 1 hour while controlling ECMO flow and O 2 flow to achieve a partial arterial pressure of oxygen (PaO 2 ) of ≥70 with partial arterial pressure of carbon dioxide (PaCO 2 ) of ≤50 and an oxygen saturation (SpO 2 ) of ≥95 at a fraction of inspired oxygen (FiO 2 ) of 0.4, positive endexpiratory pressure (PEEP) of 5 mmHg, tidal volume of 8 mL/kg, and respiratory rate of 12/min. When an ECMO support flow appropriate for transport is established, the final decision to transport is made.
Transport on ECMO
After confirming that the patient should be transported, ECMO is conducted for 15 minutes with 100% O 2 and bag ventilation using a 10 L BVM. Vital signs and blood gas levels are monitored to ensure that the patient can be maintained without a respirator, and if so, the battery charge of the ECMO apparatus is checked and the gas flow line is connected to the portable O 2 tank. Ambulatory blood pressure (ABP), SpO 2 , and heart rate, are monitored continuously with the portable monitor, and the patient is moved from the ICU to the ambulance in the ambulance bed. Once in the ambulance, the ECMO device can be connected to the vehicle's power source and the O 2 line is connected to the vehicle's O 2 tank flow line. During transport, the inflow and outflow lines and the blood color in the lines are continuously checked, and the vital signs are also monitored continuously. If the patient's SpO 2 falls below 90% and the levels of O 2 in the O 2 tank of the ambulance and the condition of the endotracheal tube are found to be adequate, arterial blood gas assessments are performed (PaO 2 , PaCO 2 , and pH; I-stat ® [Santair S.A., Greece]) and the ECMO flow and O 2 flow are adjusted to restore the SpO 2 of >90%.
As soon as the ambulance arrives to our lung transplant center, the patient is taken directly to the ICU where mechanical ventilation is immediately restarted. Chest X-ray images are obtained and if stat laboratory values indicate hypoxia, hypercapnia, and/or respiratory or metabolic acidosis, these conditions are corrected as necessary. When ECMO is to be maintained as a bridge to transplant, the patients are switched from the EBS apparatus to a MAQUET permanent life support system (PLS ® ; Maquet, Jostra Medizintechnik AG, Hirrlingen, Germany) because of the durability of the oxygenator of the latter device.
Results
Seven patients (3 men and 4 women; average age: 53.9 ± 6.85 years; range: 24 to 65 years) were transported to our hospital using the ECMO transport system between December 2011 and June 2013. Respiratory failure was caused by acute exacerbation of interstitial lung disease (ILD) in 5 patients, 1 patient had severe lung damage due to chronic obstructive pulmonary disease (COPD), and 1 patient developed acute respiratory distress syndrome (ARDS) and lung fibrosis after a near-drowning. All 7 patients were candidates for lung transplantation at the time of transport. The average Murray score was 2.94 ± 0.3 (range: 2.66-3.33), and the average PaO 2 /FiO 2 ratio was 74.62 ± 18.2 (range: 6.2-106.1). All patients met the criteria for severe respiratory failure. V-V mode ECMO was used in 5 patients. Two patients with hypotension required A-V mode ECMO to maintain blood pressure because of reduced right ventricular function due to pulmonary hypertension, which was confirmed by pretransport echocardiography ( Table 2 ). The Terumo ECMO device was used to provide ECMO support during transport in all 7 patients, and all of the patients were transported without further complication. There were no adverse incidents involving the EBS ® (Terumo Corp., Japan) ECMO device during transport, and all patients maintained stable vital signs ( Table 3) .
Four of the 7 patients underwent lung transplantation within 10.5 ± 2.3 days (range: 7-12 days) after transport. A fifth patient, the near-drowning victim who had initially been deemed to have irreversible lung failure requiring transplant, began to improve, and he was weaned from ECMO 17 days after transport and transferred to the general ward on day 26. The last 2 patients both remained on ECMO for extended periods because donors could not be found, and both developed pneumonia and sepsis and died with multiple organ failure on days 22 and 15, respectively. The 2 patients who initially required V-A mode ECMO received V-V mode ECMO after reevaluation of cardiac function, but one of these patients developed sepsis and multiple organ failure and received veno-venous-arterial (V-V-A) mode ECMO subsequently ( Table 4) . 
Discussion
Inter-hospital transport using ECMO has been evolving since the early phase of ECMO development, and since the first report of inter-hospital transport of 2 patients by Bartlett, et al., the ability of ECMO to support this procedure has been considered to be one of its important benefits. 4) Early ECMO devices used an open circuit and a centrifugal pump. The ECMO equipment was large and required a large transport team, and inter-hospital transport was only possible in a limited number of ECMO centers. However, with the introduction of a closed-circuit ECMO system and the use of a centrifugal pump, patient transport has become easier and safer, making inter-hospital transport possible for a greater number of ECMO centers. [5] [6] [7] The rate of hidden mortality of critical patients who require ECMO is approximately 10% to 12% during ambulance transport. Given that the survival rate of these patients up to discharge is approximately 55% to 60%, inter-hospital transport using ECMO could have an important role in improving survival rates. In particular, because survival among patients with respiratory failure is especially high at 60% to 80%, inter-hospital transport with ECMO for these patients might prove even more effective than similar measures for patients with other conditions. [8] [9] [10] [11] As yet, inter-hospital transport using ECMO is not commonly used for lung transplant candidates, and reports have been rare. Haneya, et al. 12) reported that ECMO or interventional lung assist (ILA) was used as bridge to transplant for 10 patients in an ECMO center that does not perform lung transplantation; 7 of these patients were ultimately transported to a remote transplantation center for lung transplant, 3 while on ECMO and 1 while on ILA. Hayes, et al. 13) reported cross-country transport for lung transplantation using bicaval double lumen catheter V-V ECMO for a 13-year-old girl.
Most reports of inter-hospital ECMO transport programs have involved transport of patients who needed ECMO from a hospital with no ECMO facilities to an ECMO center. Our program was developed specifically for transporting patients from hospitals that do not perform lung transplantation to our regional lung transplantation center. This inter-hospital ECMO program is a combination of an inter-hospital transport method and a bridge to lung transplantation, and it has allowed safe transfer of lung transplant candidates who show severe decline of lung function during treatment at a general hospital and would not have tolerated transport by routine methods. Once at our center, the patients can be supported in the appropriate intensive care unit until a lung donor is found.
Our country has a government-run network for donor organ allocation. In this system, intubated patients or ECMO patients have priority for lung transplantation. Therefore, patients who are transported to our center using ECMO as a bridge will ideally undergo lung transplantation as soon as possible.
One of the main goals during the planning of our center's ECMO transport system was to maximize the portability of the ECMO apparatus and supporting devices. Equipment and personnel requirements for transport of a patient who is in need of both a respirator and an ECMO system via ambulance may be prohibitive. Therefore, we decided to institute a transport system without a respirator. Now that awake ECMO has been introduced, it is reported that it is possible to maintain adequate SpO 2 and PCO 2 without a respirator and using only ECMO support, even in patients in severe respiratory failure with PaO 2 /FiO 2 of ≤100. As long as sufficient blood flow can be maintained, transport with ECMO and without mechanical ventilator support is possible. 14, 15) We provided respiratory support during transport using only a BVM with ECMO. All patients who were transported by our system during the present study had PaO 2 /FiO 2 ≤100 with ventilator settings for a FiO 2 of 1.0, and all tolerated the transport using only ECMO and BVM. We made the decision to transport only when SpO 2 was >95% and a stable blood pressure could be maintained by BVM and ECMO for 15 minutes prior to transport. As no patient experienced drastic changes in blood flow or SpO 2 , we demonstrated that transport with ECMO and BVM only was safe and feasible.
There are two ECMO systems that are currently available in East Asia, EBS ® (Terumo Corp., Japan) and PLS ® (Maquet, Germany). The EBS ® weighs 14 kg and is readily portable. This ECMO apparatus was designed and developed for the purpose of emergency life support, and it allows a stable blood flow even at low pump speeds. In our experience, the EBS provided a stable oxygen supply and allowed the maintenance of blood pressure during transport with a low risk of adverse events. Furthermore, the EBS has an auto-priming function for easy circuit priming, which can be crucial in the event of circuit problems during transport because it permits rapid response and exchange. While the EBS apparatus is our preferred ECMO device for inter-hospital transport with ECMO, once stable after transport, and if still a candidate for lung transplant, the patient is switched to the PLS system within 2 to 3 days. This is because the oxygenator of the EBS is made with polypropylene, and longterm use is not possible without changing the oxygenator, while the PLS is designed for long-term heart-lung support. The PLS system weighs 29 kg, and is not easily portable. Its pump cone was designed to be small, and the motor must be run at a high speed to maintain sufficient blood flow, which can cause increased negative pressure of the drainage catheter, venous line chatter, and decreased blood drainage, potentially complicating the maintenance of oxygen supply and blood pressure. 16) The PLS system does not have an automatic de-airing function during circuit priming, and a circuit change during priming, even with the help of a trained perfusionist, can be relatively time-consuming. If an emergency requiring a circuit change were to occur during transport with PLS, the patient could be in danger.
We safely transported 7 end-stage lung disease patients using an ECMO-based inter-hospital transport system, and all patients survived the transport. Four patients underwent lung transplantation, 1 patient recovered after ECMO intervention, and eventually was weaned from the ventilator, and 2 patients died while awaiting a suitable lung donor for transplant. As we are a regional lung transplantation center, we believe that programs to transport lung transplant candidates and improve the survival rate of lung transplantation must be in operation.
